Treatment patterns for ESR1-mutated advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older who has gone through menopause (either naturally or from surgery).
- Your breast cancer is advanced (spread to other parts of the body or can't be removed by surgery).
- Your cancer tests positive for estrogen receptors (ER+), negative for HER2, and has an ESR1 gene mutation.
- You have already tried at least one type of hormone therapy and your cancer continued to grow.
- You are not pregnant or breastfeeding, and you can swallow pills easily.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether routine blood tests can detect a specific genetic change (ESR1 mutation) that may make hormone therapy less effective over time. It is for people whose cancer is stable while taking a standard first-line treatment, and the results may help guide future care.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Hear when a new ESR1 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.